This steady increase in the patenting activity by the non-residents is indicative of the fact that the Patents Act, as it exists today, accommodates incremental innovations, since the patents granted are not only for new molecules but also for new processes as well as new uses, combinations and dosage forms. During the last three years alone, the Indian Patent Office has granted 3506 patents relating to pharmaceutical innovations. Therefore, on the basis of experience of the last four years it cannot be argued that section 3(d) was against incremental innovations.